Shots:

• Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque- Omniscan- including Visipaque- Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020
• GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the products till Mar’2022 and later transfer the rights to GE Healthcare
• Omnipaque (Iohexol) is a contrast agent used in X-rays to visualize arteries- veins- ventricles of the brain- the urinary system & joints. Omniscan is a gadolinium-based contrast agent used in MRI to visualize lesions with abnormal vascularity. Sonazoid & Visipaque are the contrasting agent for ultrasonography and CT scans respectively

 Click here to read full press release/ article 

Ref: Daiichi Sankyo | Image: Logos